BioNTech SE
PublicBioNTech SE is now publicly traded
The data on this page reflects BioNTech SE's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Oct 10, 2019
Last Round
Grant
May 20, 2025
Total Funding Raised
$1.87B
Company Overview
BioNTech SE operates in Healthcare and is based in Mainz, Rhineland-Palatinate. It has raised $1.87B.
BioNTech SE is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
Sector
Healthcare
AI Layer
Application
BioNTech SE Comparables
Compare BioNTech SE with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genevation LTD | 63% | |
| NeoCura Bio-Medical Technology Co., Ltd. | 60% | |
| ViferaXS GmbH | 60% |
For institutional investors. Book with your work email.
BioNTech SE Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | May 20, 2025 | ||||
| Follow-on Offering | Jul 27, 2020 | ||||
| Debt | Jun 11, 2020 | ||||
| Debt | Dec 17, 2019 | ||||
| IPO | Oct 10, 2019 | ||||
Strategic | Aug 30, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
BioNTech SE Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series B, Series A |
| Janus Henderson Group | Series B, Series A |
| Temasek | Debt |
| MIG Capital | Seed |
| UK government | Grant |
| Bryan, Garnier & Co. | Follow-on Offering, IPO |
| Canaccord Genuity | Follow-on Offering, IPO |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- has_issues_withNov 6, 2026
BioNTech SE faces issues over patent royalties for technology used in COVID vaccines as part of a web of US court cases involving Pfizer, BioNTech and Moderna on Nov 6th '26.
- is_developingNov 5, 2026
BioNTech SE participates in a new global Phase 3 collaboration to test the combination treatment for metastatic triple-negative breast cancer with BioNTech.
- has_revenueNov 3, 2026
BioNTech SE records $685M in Q3 '26 revenue from its global partnership with Bristol Myers Squibb to co-develop and co-commercialize pumitamig, its PD-L1- and VEGF-A-targeting bispecific antibody candidate.
- has_revenueNov 3, 2026
BioNTech SE has $1.7B in revenue in the comparable quarter of the previous year, while Q3 '26 revenue amounts to €1.29B.
- has_revenueNov 3, 2026
BioNTech SE reports $1.46B in third-quarter 2026 revenue, with lower demand for its COVID-19 vaccine weighing on results.
For institutional investors. Book with your work email.
BioNTech SE Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.